In this video, Dr. Greg Randolph of Harvard Medical School discusses real-world considerations for neoadjuvant therapy in advanced thyroid cancer, emphasizing the differences between controlled clinical trial populations and more heterogeneous real-world patients who may face risks such as bleeding or fistula formation. He highlights ongoing efforts by the International Thyroid Oncology Group (ITOG) to establish a global real-world registry to better understand outcomes.
Dr. Randolph also reflects on the value of multidisciplinary collaboration and shares his vision for the future of thyroid and neck surgery, including integrated technologies such as neural monitoring, parathyroid autofluorescence, OCT imaging, and potential AI-enhanced, headset-based visualization systems that could allow surgeons to access expert input in real time.